Pancreatic cancer is characterized by multiple genomicalterations, including KRAS mutations, TP53 mutations and CDKN2A deletion.However, the prognostic relevance of those genomic alterations and associatedtranscriptomic profiling in pancreatic cancer are unclear. This evidence concerns the gene KRAS and pancreatic neoplasm.